This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PSMA4 · Western blot design guide
PSMA4 Western Blot Planning Guide
Plan a PSMA4 Western blot around the catalog-observed 29.5 kDa band, image-backed PB10090 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
PSMA4 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 29.5 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Placenta | |
| Negative control | Skeletal muscle |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 29.5 kDa |
| ⓘ | Localization | Cytoplasm / Nucleus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated PSMA4 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Placenta |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, short transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB10090 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected PSMA4 Western Blot Band Size?
Use the product-observed 29.5 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 29.5 kDa | Matches the authoritative product WB observation. |
| 29.5 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected PSMA4 appearancePlan around 29.5 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 29.5 kDa; use this as the primary experimental expectation. |
| Calculated mass | 29.5 kDa from UniProt P25789; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB10090. |
| Situation | Likely cause | Next action |
|---|---|---|
| 29.5 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing PSMA4 band
PB10090 · PSMA4
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for PSMA4 Western blot
🧪Use Placenta as the first positive-control candidate and Skeletal muscle as the HPA Not detected negative candidate.
Positive control: Placenta (High)
Negative control: Skeletal muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for PSMA4
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Placenta | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Bone marrow | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced PSMA4 Western Blot Tips
Deeper troubleshooting and optimisation questions for PSMA4, answered from its protein features.
Which band should guide the blot?
Use 29.5 kDa, the observation attached to the authoritative PB10090 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 29.5 kDa expectation.
Which positive control should I start with?
Start with Placenta, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Skeletal muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for PSMA4 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB10090 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC11374303, PMC10252828, PMC11971155.
Boster reagents
PSMA4 Western Blot Reagents
Human/Mouse/Rat-reactive PSMA4 Western blot reagents with authoritative product imagery.
Real WB data
Anti-PSMA4 Antibody Picoband®
Cat # PB10090
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P25789
- Human Protein Atlas — PSMA4
- PB10090 product record
- PMC11374303 — Quantitative mapping of proteasome interactomes and substrates using ProteasomeID.
- PMC10252828 — Proteasomes of Autophagy-Deficient Cells Exhibit Alterations in Regulatory Proteins and a Marked Reduction in Activity.
- PMC11971155 — Metabolic reprogramming induced by PSMA4 overexpression facilitates bortezomib resistance in multiple myeloma.